Rentschler Biopharma marks construction milestone at new German buffer media facility
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
List view / Grid view
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
A UK CDMO is now permitted through MHRA certification to produce clinical supply of gene therapy AAV, including bioprocess through to cGMP manufacturing.
The CGT Catapult and two other collaborators have agreed to work together and use advanced process analytical technologies (PAT) to improve the process and efficiency of gene therapy AAV manufacturing.
A multi-million investment is set to enhance UK medicines manufacturing in three key areas: intracellular drug delivery, digitalisation and automation and nucleic acid medicines.
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.